65,437 trials
Ankylosing Spondylitis
Primary: Frequency of Extra-Axial Manifestations (EAMs) of Interest — 46.27; 33.33; 2.99 Percentage of participants
Acellular Pertussis · Tetanus · Diphtheria
Primary: Number of Subjects With Anti-diphtheria (Anti-DT) and Anti-tetanus Toxoid (Anti-TT) Antibody Concentrations Equal to or Above (≥) 0.1 International Units Per Milliliter…
Cocaine Dependence
Primary: Number of Participants That Achieved Study Compliance — 22; 15; 18 Participants
Allergic Conjunctivitis
Primary: Ocular Itching Change From Baseline to Day 11 — -1.1; -0.45 units on a scale
Obstructive Sleep Apnea · Snoring
Primary: Apnea-Hypopnea Index (AHI) — 30.0 events/hour — p=0.0559
Spasticity
Primary: Least Square Mean Difference (Placebo Versus Each SPARC1103 Dose) in Change From Baseline in Modified Ashworth Score — 0.33; 0.03 score on a scale
Healthy Volunteers
Primary: Part 1: Number of Participants With Abnormal Findings in Physical Examinations — 2; 1; 0; 1 Participants
Lower Respiratory Tract Infection (LRTI)
Primary: Total Antibiotic Exposure Days — 4.2; 4.3 days — p=0.87
Lysosomal Acid Lipase Deficiency
Primary: Participants Experiencing Severe Treatment-emergent Adverse Events (TEAEs) — 1; 1; 2 Participants
Diabetes · Wound Infection · Healthy Volunteers
Primary: Ceftolozane Tissue Penetration — 0.75; 0.87 ratio
Psoriasis Vulgaris
Primary: The Percentage Change in Psoriasis Area and Severity Index (PASI) of the Face Last Observation Carried Forward (LOCF) at End of Treatment — -60.8; -54.2 percentage of…
Healthy
Primary: Peak Plasma Concentration (Cmax) of Bupropion — 91.28; 76.94; 92.21; 95 ng/mL
Healthy Participants
Primary: Cmax: Maximum Observed Plasma Concentration for TAK-954 — 2.642; 2.840 nanogram/milliliter (ng/mL)
Hepatic Steatosis
Primary: Hepatic Triglyceride (%) — 15.9; 14.8 Fat/Fat+Water (%) — p=0.42
Diabetes · Wound Infection · Healthy Volunteers
Primary: Tedizolid Tissue Penetration — 0.98; 0.82 ratio